Transplacental passage of ritonavir-boosted darunavir in two pregnant women

International Journal of STD and AIDS

Volumn 20, Issue 3, 2009, Pages 215-216

  Ripamonti, D ^a   Cattaneo, D ^b,c   Cortinovis, M ^b,c   Maggiolo, F ^a   Suter, F ^a  

^a Division of Infectious Diseases   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE;

ADULT; ANAMNESIS; CASE REPORT; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FETOMATERNAL TRANSFUSION; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MONOTHERAPY; PREGNANCY; PRIORITY JOURNAL; VIRUS LOAD; VIRUS TRANSMISSION;

FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RITONAVIR; SULFONAMIDES;

EID: 62249218967     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008515     Document Type: Letter

References (11)

1. Centers for Disease Control and Prevention. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. See http://www.guideline.gov/ (last accessed December 2008)
2. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008;22:973-81
3. Warszawski J, Tubiana R, Le Chenadec J, et al.; for ANRS French Perinatal Cohort. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French perinatal cohort. AIDS 2008;22:289-99
4. Clotet B, Bellos N, Molina JM, et al.; for POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78
5. Department of Health and Human Services. AIDS info - HIV/AIDS Drug Information - Darunavir. See http://www.aidsinfo.nih.gov/DrugsNew
6. Goldwirt L, Chhun S, Rey E, et al. Quantification of darunavir (TMC114) in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007;857:327-31
7. Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002;16:889-93
8. Gingelmaier A, Kurowski M, Kastner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006;20:1737-43
9. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006;20:1931-9
10. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007;21:2409-15
11. Back D, Sekar V, Hoetelmans RM. Darunavir: pharmacokinetics and drug interactions (Review). Antivir Ther 2008;13:1-13